ABIOMED, Inc. (ABMD) Position Raised by Aperio Group LLC

Aperio Group LLC increased its holdings in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 29.0% in the 4th quarter, Holdings Channel reports. The firm owned 17,706 shares of the medical equipment provider’s stock after acquiring an additional 3,977 shares during the quarter. Aperio Group LLC’s holdings in ABIOMED were worth $3,318,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the stock. Sterling Capital Management LLC lifted its stake in ABIOMED by 2.2% during the third quarter. Sterling Capital Management LLC now owns 13,139 shares of the medical equipment provider’s stock worth $2,215,000 after purchasing an additional 281 shares during the last quarter. Comerica Bank lifted its stake in ABIOMED by 0.9% during the fourth quarter. Comerica Bank now owns 33,144 shares of the medical equipment provider’s stock worth $7,721,000 after purchasing an additional 293 shares during the last quarter. State of Wisconsin Investment Board lifted its stake in ABIOMED by 3.6% during the third quarter. State of Wisconsin Investment Board now owns 8,364 shares of the medical equipment provider’s stock worth $1,410,000 after purchasing an additional 294 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in ABIOMED by 2.7% during the third quarter. Oregon Public Employees Retirement Fund now owns 15,023 shares of the medical equipment provider’s stock worth $2,533,000 after purchasing an additional 397 shares during the last quarter. Finally, LS Investment Advisors LLC lifted its stake in ABIOMED by 9.8% during the third quarter. LS Investment Advisors LLC now owns 4,874 shares of the medical equipment provider’s stock worth $822,000 after purchasing an additional 437 shares during the last quarter. Hedge funds and other institutional investors own 90.35% of the company’s stock.

Shares of ABIOMED, Inc. (ABMD) opened at $267.74 on Friday. ABIOMED, Inc. has a 52 week low of $110.61 and a 52 week high of $268.72. The firm has a market capitalization of $12,140.00, a P/E ratio of 108.84, a price-to-earnings-growth ratio of 3.46 and a beta of 0.36.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.20. ABIOMED had a return on equity of 15.54% and a net margin of 16.58%. The company had revenue of $154.00 million during the quarter, compared to analysts’ expectations of $154.00 million. During the same quarter in the previous year, the business earned $0.34 earnings per share. The firm’s revenue for the quarter was up 34.9% on a year-over-year basis. analysts expect that ABIOMED, Inc. will post 2.39 earnings per share for the current fiscal year.

ABMD has been the subject of several recent analyst reports. Zacks Investment Research upgraded ABIOMED from a “sell” rating to a “buy” rating and set a $203.00 target price for the company in a research note on Monday, October 30th. Jefferies Group boosted their target price on ABIOMED to $250.00 and gave the stock a “buy” rating in a research note on Friday, January 12th. SunTrust Banks restated a “buy” rating and set a $195.00 target price on shares of ABIOMED in a research note on Wednesday, November 1st. Piper Jaffray Companies boosted their target price on ABIOMED to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, October 26th. Finally, BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. ABIOMED presently has a consensus rating of “Buy” and a consensus target price of $288.86.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/02/18/abiomed-inc-abmd-position-raised-by-aperio-group-llc.html.

ABIOMED Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply